Launch of a pioneering translational research programme in Europe

– The TRIP initiative establishes three new joint laboratories that bring together fundamental biomedical research and clinical research with the aim of accelerating the delivery of results to patients.
– TRIP will focus on emerging fields such as immuno-oncology, inflammation, and cellular senescence.

Cleveland Clinic Researchers Uncover How Virus Causes Cancer, Point to Potential Treatment

Cleveland Clinic researchers have discovered a key mechanism used by Kaposi’s sarcoma-associated herpesvirus (KSHV), also known as human herpesvirus 8 (HHV8), to induce cancer. The research points to effective new treatment options for KSHV-associated cancers, including Kaposi’s sarcoma, primary effusion lymphoma, and HHV8-associated multicentric Castleman disease.

ASCO23: Sylvester Cancer Experts Available for Interviews on a Wide Range of Topics

In addition to presenting Sylvester Comprehensive Cancer Center research findings, Sylvester experts are available at ASCO to share perspectives on a wide variety of topics and studies ranging from breast cancer to sarcoma, prostate cancer, mesothelioma, melanoma, CNS tumors and more.

Cedars-Sinai Cancer Experts To Present Clinical Findings at AACR Conference

Cedars-Sinai Cancer oncologists and researchers are available to comment on late-breaking topics and research throughout the American Association for Cancer Research (AACR) Annual Meeting 2023, happening April 14-19 in Orlando.

Discovery of cell protein that keeps Kaposi’s sarcoma herpesvirus dormant

A study led by UC Davis Cancer Center identified a binding protein in cancer cell’s nucleus, known as CHD4, as a critical agent keeping Kaposi’s sarcoma-associated herpesvirus (KSHV) dormant and undetected by the body’s immune system. CHD4 is linked to cancer cell growth in many types of cancers.